Bladder-sparing radiotherapy for muscle-invasive bladder cancer: A survey of providers to determine barriers and enablers.

Radiother Oncol

Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Canada; Department of Oncology, Queen's University, Canada; Department of Public Health Sciences, Queen's University, Canada. Electronic address:

Published: November 2017

Background: To understand barriers and enablers to use of curative-intent radiotherapy (RT) for muscle-invasive bladder cancer using the Theoretical Domains Framework (TDF).

Methods: Canadian urologists, radiation oncologists (ROs) and medical oncologists (MOs) participated in a web-based survey to assess barriers and enablers to use of RT. Survey questions were thematically mapped to TDF domains. Logistic regression was used to identify TDF domains associated with high referral/use of RT.

Results: 64 urologists, 29 ROs and 26 MOs participated. Participants reported comparable survival at five years with cystectomy (51%) and RT with concurrent chemotherapy (50%). Despite this, participants reported low RT referral/treatment rates: Urologists referred a median of 2/10 patients to RO; ROs treated a median of 5/10 patients referred; and MOs referred a median of 2/8 patients not referred to RO by urology. Among urologists, the TDF domains 'beliefs about consequences' (OR=8.1, 95% CI 1.5-44.9), 'social and professional role' (OR=11.2, 95% CI 2.3-53.6) and 'environmental context and resources' (OR=5.9, 95% CI 1.5-23.3) were associated with higher rates of RO referral.

Conclusions: We have identified factors associated with referral for RT among patients with bladder cancer. These factors should be addressed as part of a concerted effort to increase utilization of RT.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.radonc.2017.08.036DOI Listing

Publication Analysis

Top Keywords

bladder cancer
12
barriers enablers
12
tdf domains
12
radiotherapy muscle-invasive
8
muscle-invasive bladder
8
mos participated
8
participants reported
8
referred median
8
patients referred
8
bladder-sparing radiotherapy
4

Similar Publications

Background: To report the first case series of RARC using a simplified technique for intracorporeal stentless neobladder formation.

Methods: From October 2022 to February 2023, 10 patients with high-risk bladder cancer underwent RARC at our Institution. RARC with extended pelvic lymph node dissection and totally intracorporeal neobladder using Hugo RAS system.

View Article and Find Full Text PDF

Introduction: Small cell neuroendocrine carcinoma of the urinary tract (SCNEC-URO) has an inferior prognosis compared to conventional urothelial carcinoma (UC). Here, we evaluate the predictors and patterns of relapse after surgery.

Materials And Methods: We identified a definitive-surgery cohort (n = 224) from an institutional database of patients with cT1-T4NxM0 SCNEC-URO treated in 1985-2021.

View Article and Find Full Text PDF

Background: Urinary system tumors often cause negative psychological symptoms, such as depression and dysphoria which significantly impact immune function and indirectly affect cancer prognosis. While epirubicin (EPI) is recommended by the European Association of Urology and can improve prognosis, its long-term use can cause toxic side effects, reduce treatment compliance, and increase psychological burden. Therefore, an appropriate intervention mode is necessary.

View Article and Find Full Text PDF

Acute myeloid leukemia (AML) can be presented with extramedullary manifestations, more frequently involving skin and rarely other sites, such as the urinary tract. We report the case of a 37-year-old male patient with a history of testicular cancer who presented to the emergency department with cytopenias and hematuria. Bone marrow analysis diagnosed AML (French-American-British(FAB) classificationM4 subtype, karyotype showing inv16).

View Article and Find Full Text PDF

Proteolysis targeting chimeras (PROTACs) are pivotal in cancer therapy for their ability to degrade specific proteins. However, their non-specificity can lead to systemic toxicity due to protein degradation in normal cells. To address this, we have integrated a nanobody into the PROTACs framework and leveraged the tumor microenvironment to enhance drug specificity.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!